Related Experiment Video
Updated: Aug 1, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Luteolin Mitigates Diabetic Dyslipidemia in Rats by Modulating ACAT-2, PPARα, SREBP-2 Proteins, and Oxidative Stress
Syed Ilyas Shehnaz1, Anitha Roy2, Rajagopalan Vijayaraghavan3
1Department of Pharmacology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, 602105, Tamil Nadu, India. shehnazilyas@yahoo.com.
Abstract:
Diabetic dyslipidemia is a crucial link between type-2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular diseases (ASCVD). Natural biologically active substances have been advocated as complementary remedies for ASCVD and T2DM. Luteolin, a flavonoid, exhibits antioxidant, hypolipidemic, and antiatherogenic effects. Hence, we aimed to determine influence of luteolin on lipid homeostasis and hepatic damage in rats with T2DM induced by high-fat-diet (HFD) and streptozotocin (STZ). After being fed HFD for 10 days, male Wistar rats received 40 mg/kg STZ intraperitoneal injection on 11th day. Seventy-two hours later, hyperglycemic rats (fasting glucose > 200 mg/dL) were randomized into groups, and oral hydroxy-propyl-cellulose, atorvastatin (5 mg/kg), or luteolin (50 mg/kg or 100 mg/kg) administered daily, while continuing HFD for 28 days. Luteolin significantly ameliorated dyslipidemia levels and concomitantly improved atherogenic index of plasma in a dose-dependent manner. Increased levels of malondialdehyde and diminished levels of superoxide dismutase, catalase, and glutathione in HFD-STZ-diabetic rats were significantly regulated by luteolin. Luteolin significantly intensified PPARα expression while decreasing expression of acyl-coenzyme A:cholesterol acyltransferase-2 (ACAT-2) and sterol regulatory element binding protein-2 (SREBP-2) proteins. Moreover, luteolin effectively alleviated hepatic impairment in HFD-STZ-diabetic rats to near-normal control levels. The findings of the present study expound mechanisms by which luteolin mitigated diabetic dyslipidemia and alleviated hepatic impairment in HFD-STZ-diabetic rats by amelioration of oxidative stress, modulation of PPARα expression, and downregulation of ACAT-2 and SREBP-2. In conclusion, our results imply that luteolin may be efficacious in management of dyslipidemia in T2DM, and future research may be essential to substantiate our findings.
Insights
Luteolin, a natural flavonoid, effectively improved lipid profiles and reduced liver damage in diabetic rats. This suggests luteolin
Area of Science:
- Biochemistry
- Pharmacology
- Endocrinology
Background:
- Diabetic dyslipidemia links type-2 diabetes mellitus (T2DM) to cardiovascular disease.
- Natural compounds like luteolin show potential for managing T2DM and related complications.
- Luteolin possesses antioxidant, hypolipidemic, and antiatherogenic properties.
Purpose of the Study:
- To investigate the effects of luteolin on lipid homeostasis and liver damage in a rat model of T2DM.
- To elucidate the underlying mechanisms of luteolin's action in diabetic dyslipidemia.
Main Methods:
- Type-2 diabetes mellitus was induced in Wistar rats using a high-fat diet (HFD) and streptozotocin (STZ).
- Diabetic rats were treated with varying doses of luteolin, atorvastatin, or a control.
- Lipid profiles, atherogenic index, oxidative stress markers, and hepatic function were assessed.
- Expression levels of key proteins (PPARα, ACAT-2, SREBP-2) were analyzed.
Main Results:
- Luteolin significantly improved lipid profiles and reduced the atherogenic index in a dose-dependent manner.
- Luteolin ameliorated oxidative stress by regulating malondialdehyde, superoxide dismutase, catalase, and glutathione levels.
- Luteolin modulated PPARα expression and downregulated ACAT-2 and SREBP-2, alleviating hepatic impairment.
Conclusions:
- Luteolin demonstrates efficacy in managing diabetic dyslipidemia and associated hepatic damage in T2DM rats.
- Mechanisms include amelioration of oxidative stress and modulation of lipid metabolism-related protein expression.
- Further research is warranted to confirm luteolin's therapeutic potential for T2DM patients.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management